Skip to main content
main-content

12-12-2019 | Breast cancer | Video

SABCS 2019 | HER2CLIMB: Tucatinib shows promise for HER2-positive metastatic breast cancer

Rashmi Murthy reports on the HER2CLIMB study pointing to a role for the selective HER2–tyrosine kinase inhibitor tucatinib in the metastatic breast cancer setting (3:12).

Funding for independent interviews at SABCS 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits